Reclaim Your Sight: How Minimally Invasive Glaucoma Surgery And Microshunts Are Changing The Game

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision.

In 1999, I defined regenerative medicine as the collection of interventions that restore to normal function tissues and organs that have been damaged by disease, injured by trauma, or worn by time. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

Primary open-angle glaucoma is a chronic eye disease that causes progressive damage to the optic nerve over time. This damage often results in a gradual loss of vision, which can ultimately lead to blindness if left untreated. Unlike other types of glaucoma, OAG typically develops without noticeable symptoms at first, which is why it's often called the"silent thief of sight."but it is suggested that 57.

Canal-based devices increase the drainage of aqueous humor, the fluid that fills the front of the eye. On the other hand, suprachoroidal-based devices work by shunting fluid from the front of the eye to the space between the sclera and the choroid, a layer of blood vessels in the eye.. A bleb is a fluid-filled pocket that forms under the conjunctiva, the thin membrane covering the eye's white part. The formation and management of the bleb play a critical role in surgical success.

Still, MIGS devices like the MicroShunt offer a promising option for POAG patients as they are less invasive and effective than traditional glaucoma surgeries. While there are potential risks and complications associated with any surgical procedure, the MicroShunt has demonstrated effectiveness in reducing IOP and preserving vision.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Can Light And Sound Therapy Treat Alzheimer’s Disease? Part 2I am a scientist, businessman, author, and philanthropist. For nearly two decades, I was a professor at Harvard Medical School and Harvard School of Public Health where I founded two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology.
Source: ForbesTech - 🏆 318. / 59 Read more »

How Regulatory T Cells Can Reduce Solid Tumors In MiceI am a scientist, businessman, author, and philanthropist. For nearly two decades, I was a professor at Harvard Medical School and Harvard School of Public Health where I founded two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology.
Source: ForbesTech - 🏆 318. / 59 Read more »